Brief: AroCell: TK1 Can Be Used For Early Detection Of Therapy Response In Breast Cancer Treatment

IDL Diagnostics AB (publ)

19/09/2019 07:59

Sept 19 (Reuters) - AroCell AB  AROC.ST :
    * SAID ON WEDNESDAY THYMIDINE KINASE 1 CAN BE USED FOR EARLY
DETECTION OF THERAPY RESPONSE IN BREAST CANCER TREATMENT 
    * RESULTS SHOW THAT A TK1-BASED CELL-LOSS METRIC AFTER TWO
CYCLES
OF THERAPY PREDICTED THE STATUS AT THE OPERATION AFTER SIX
CYCLES OF CHEMOTHERAPY
    * CONCENTRATION OF TK1 IN BLOOD WAS MEASURED WITH TK 210
ELISA
    * STUDY CONCLUDES THAT TK1 HAS THE POTENTIAL TO BE OF GREAT
VALUE
FOR EARLY PREDICTION ON RESPONSE OF CYTOSTATIC TREATMENT FOR
PATIENTS WITH BREAST CANCER

    
 Source text for Eikon:  urn:newsml:reuters.com:*:nGNE2HMqvY
    
 Further company coverage:  AROC.ST  
   
    
    

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 7720920;))